You are here: Home » International » News » Others
Business Standard

US, AstraZeneca strike deal for Covid-19 antibody treatment touted by Trump

The US government has awarded $486 mn to AstraZeneca Plc to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment

Coronavirus | AstraZeneca | Donald Trump


Photo: Reuters
Photo: Reuters

(Reuters) - The U.S. government has awarded $486 million to Plc to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment, a similar class of drug that was used in treating President

The agreement, under the Trump administration's Operation Warp Speed, is for developing a monoclonal antibody cocktail that can prevent COVID-19, especially in high-risk population like those over 80 years old, the U.S. Department of Health and Human Services said.

The treatment has come under the spotlight after Trump was treated with Regeneron Pharmaceuticals' antibody drug last week. The president has also released a video on Twitter touting its benefits.

In a call earlier on Friday, a top U.S. health official said the government was expecting to provide more than 1 million free doses of antibody treatments to COVID-19 patients, similar to the one that was administered to Trump.

Regeneron and Eli Lilly have both applied to the U.S. Food and Drug Administration for emergency use authorizations of their antibody treatments.

said it was planning to supply up to 100,000 doses starting toward the end of 2020 and that the U.S. government could acquire up to an additional one million doses in 2021 under a separate agreement.

Regeneron signed a $450 million deal in July to sell Operation Warp Speed enough doses of its antibody treatment, REGN-COV2, to treat around 300,000 people.

Eli Lilly said on Friday it had not signed an agreement with Operation Warp Speed.

plans to evaluate the treatment, AZD7442, which is a cocktail of two monoclonal antibodies, in two studies.

One trial will evaluate the safety and efficacy of the experimental treatment to prevent infection for up to 12 months in about 5,000 participants, while the second will evaluate post-exposure preventative and pre-emptive treatment in roughly 1,100 participants.


(Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D'Silva)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, October 10 2020. 09:42 IST